Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis.
Biosimilars
CD20
DLBCL
Overall survival
Reditux
Rituximab
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
10
05
2019
accepted:
26
07
2019
entrez:
17
3
2020
pubmed:
17
3
2020
medline:
17
3
2020
Statut:
ppublish
Résumé
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma among adults, although it also affects the young and the elderly. DLBCL is treated with a chimeric monoclonal antibody against CD20, a B cell surface protein, named rituximab, in combination with a multidrug chemotherapeutic regimen. However, owing to its high cost, rituximab cannot be afforded by patients in developing or underdeveloped countries. In such cases, biosimilars of rituximab have been used instead of rituximab, with equivalent efficacy. In this single center, retrospective, observational study, we have compared patient outcomes such complete response (CR), partial response (PR), and overall response rate (ORR) in a cohort of 152 patients in an Indian hospital, who were treated either with innovator rituximab or Reditux, a biosimilar. We observed that the ORRs of both groups (88% in innnovator group and 82% in biosimilar group) were comparable. There was no statistically significant difference between the two groups in terms of CR (
Identifiants
pubmed: 32174693
doi: 10.1007/s12288-019-01167-w
pii: 1167
pmc: PMC7042466
doi:
Types de publication
Journal Article
Langues
eng
Pagination
71-77Informations de copyright
© Indian Society of Hematology and Blood Transfusion 2019.
Déclaration de conflit d'intérêts
Conflict of interestAll authors declare that they have no conflict of interest.
Références
J Clin Oncol. 2014 Sep 20;32(27):3059-68
pubmed: 25113753
Blood. 1997 Jun 1;89(11):3909-18
pubmed: 9166827
Lancet Haematol. 2017 Aug;4(8):e362-e373
pubmed: 28712940
Indian J Cancer. 2017 Apr-Jun;54(2):430-435
pubmed: 29469072
Lancet Haematol. 2018 Nov;5(11):e543-e553
pubmed: 30389036
Lancet Oncol. 2011 Oct;12(11):1013-22
pubmed: 21940214
Adv Ther. 2017 May;34(5):1128-1144
pubmed: 28397080
Biosimilars. 2013 Jun 14;2013(3):19-25
pubmed: 24829884
BioDrugs. 2017 Aug;31(4):357-367
pubmed: 28612179
Lancet Haematol. 2017 Aug;4(8):e350-e361
pubmed: 28712941
Cancer Chemother Pharmacol. 2016 Aug;78(2):353-9
pubmed: 27329361
Lancet Haematol. 2017 Aug;4(8):e341
pubmed: 28754191
Indian J Med Paediatr Oncol. 2013 Oct;34(4):292-8
pubmed: 24604960
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
Br J Clin Pharmacol. 2016 Jul;82(1):129-38
pubmed: 26909489